Comparable Ablation Efficiency of 30 and 100 mCi of I-131 in Low to Intermediate Risk Thyroid Cancers Using Triple Negative Criteria

被引：0
|
作者：
Zaman, M. U. [1 ]
Fa, N. [2 ]
Zaman, A. [3 ]
Zaman, U. [3 ]
Tahseen, R. [3 ]
机构：
[1] AKUH, Karachi, Pakistan
[2] Dr Ziauddin Hosp, Karachi, Pakistan
[3] Dow Univ Hlth Scineces, Karachi, Pakistan
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2016年 / 43卷
关键词：
Radioiodine ablation; differentiated thyroid cancer; successful ablation; low dose; high dose; stimulated thyroglobulin;
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP357
引用
收藏
页码：S372 / S373
页数：2
相关论文
共 12 条
  • [1] Comparison of 30 mCi and 50 mCi I-131 doses for ablation of thyroid remnant in papillary thyroid cancer patients
    Cai, Xiao Yue
    Vijayaratnam, Niranjan
    McEwan, Alexander J. B.
    Reif, Rebecca
    Morrish, Donald W.
    ENDOCRINE RESEARCH, 2018, 43 (01) : 11 - 14
  • [2] Factors Affecting Ablation Success After I-131 Radioactive Iodine Therapy in Low and Intermediate Risk Papillary Thyroid Cancer
    Goksel, Sibel
    Avci, Ugur
    HORMONE AND METABOLIC RESEARCH, 2023, 55 (10) : 677 - 683
  • [3] Correlation analysis of I-131 SPECT/CT uptake parameters with the success ablation treatment of thyroid remnant in patients with low-intermediate-risk differentiated thyroid cancer
    Zhang, Qian
    Xu, Weina
    NUCLEAR MEDICINE COMMUNICATIONS, 2022, 43 (10) : 1051 - 1057
  • [4] Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma
    Marin Prpic
    Ivan Kruljac
    Davor Kust
    Lora S. Kirigin
    Tomislav Jukic
    Nina Dabelic
    Ante Bolanca
    Zvonko Kusic
    Endocrine, 2016, 52 : 602 - 608
  • [5] Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma
    Prpic, Marin
    Kruljac, Ivan
    Kust, Davor
    Kirigin, Lora S.
    Jukic, Tomislav
    Dabelic, Nina
    Bolanca, Ante
    Kusic, Zvonko
    ENDOCRINE, 2016, 52 (03) : 602 - 608
  • [6] Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy
    Aicar Suss, Shirlei Kugler
    Mesa Jr, Cleo Otaviano
    de Carvalho, Gisah Amaral
    Miasaki, Fabiola Yukiko
    Chaves, Carolina Perez
    Fuser, Dominique Cochat
    Corbo, Rossana
    Momesso, Denise
    Bulzico, Daniel A.
    Graf, Hans
    Vaisman, Fernanda
    ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2018, 62 (02): : 149 - 156
  • [7] Is radioiodine ablation with 1.1 GBq (30 mCi) 131I necessary in low-risk thyroid cancer patients? Results from a long-term follow-up prospective study
    Ilera, Veronica
    Califano, Ines
    Cavallo, Andrea
    Faure, Eduardo
    Vazquez, Adriana
    Pitoia, Fabian
    ENDOCRINE, 2023, 80 (03) : 606 - 611
  • [8] Outpatient Thyroid Remnant Ablation Using Repeated Low 131-Iodine Activities (740 MBq/20 mCi x 2) in Patients with Low-Risk Differentiated Thyroid Cancer
    Clerc, Jerome
    Bienvenu-Perrard, Marie
    de Malleray, Caroline Pichard
    Dagousset, Francoise
    Delbot, Thierry
    Dreyfuss, Marc
    Groussin, Lionel
    Marlowe, Robert J.
    Leger, Francoise Aubene
    Chevalier, Alain
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (03) : 871 - 880
  • [9] Is radioiodine ablation with 1.1 GBq (30 mCi) 131I necessary in low-risk thyroid cancer patients? Results from a long-term follow-up prospective study
    Verónica Ilera
    Inés Califano
    Andrea Cavallo
    Eduardo Faure
    Adriana Vázquez
    Fabián Pitoia
    Endocrine, 2023, 80 : 606 - 611
  • [10] Combined clinical variable and radiomics of post-treatment total body scan for prediction of successful I-131 ablation in low-risk papillary thyroid carcinoma patients
    Chantadisai, Maythinee
    Wongwijitsook, Jirarot
    Ritlumlert, Napat
    Rakvongthai, Yothin
    SCIENTIFIC REPORTS, 2024, 14 (01)
12